Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
Ralph V. Boccia
No relevant relationships to disclose
William Cooper
Consultant or Advisory Role - TFS
Erin O'Boyle
Consultant or Advisory Role - A.P. Pharma
Stock Ownership - A.P. Pharma